Skip to main content
. 2022 Oct 17;14(20):5078. doi: 10.3390/cancers14205078

Figure 1.

Figure 1

Study flowchart. CONSORT diagram of patients treated with an antiPD-(L)1 monotherapy between 2014 and 2017 in real-life situation, i.e., following marketing authorization, part of an early access program for unlicensed indications or upon compassionate use at Gustave Roussy.